25 results for “narcolepsy”. Showing 25 of 39,449.
Challenges in the development of therapeutics for narcolepsy.
Narcolepsy is a neurological disorder that afflicts 1 in 2000 individuals
Epigenetic silencing of selected hypothalamic neuropeptides in narcolepsy with cataplexy.
Narcolepsy with cataplexy is a sleep disorder caused by deficiency
Mechanistic insights into influenza vaccine-associated narcolepsy.
narcolepsy and vaccine-induced narcolepsy will be provided. Then, additional
Hypocretin receptor expression in canine and murine narcolepsy models and in hypocretin-ligand deficient human narcolepsy.
narcolepsy. DESIGN: Animal and human study. We measured hcrtR1 and hcrtR2
Connecting the dots: An updated review of the role of autoimmunity in narcolepsy and emerging immunotherapeutic approaches.
Narcolepsy type 1 (NT1) is a chronic disorder characterized by pathological
Oral Orexin Receptor 2 Agonist in Narcolepsy Type 1.
narcolepsy type 1. Patients with confirmed narcolepsy type 1 according
Prader Willi syndrome and obstructive sleep apnea: co-occurrence in the pediatric population.
narcolepsy among children with PWS. Screening for OSA and narcolepsy
Orexin 2 receptor-selective agonist danavorexton improves narcolepsy phenotype in a mouse model and in human patients.
Narcolepsy type 1 (NT1) is a sleep disorder caused by a loss
Discovery of Arylsulfonamides as Dual Orexin Receptor Agonists.
narcolepsy with cataplexy, and orexin agonists have been shown to increase
Almorexant promotes sleep and exacerbates cataplexy in a murine model of narcolepsy.
narcolepsy and orexin/ataxin-3 transgenic (TG) mice exhibit extensive, but incomplete
Hypocretin/orexin, sleep and narcolepsy.
narcolepsy, a disorder associated with excessive daytime sleepiness, cataplexy and unusually
Effects of Oveporexton, an Orexin Receptor 2-Selective Agonist, on Cognition in Narcolepsy Type 1: A Secondary Analysis of a Randomized Clinical Trial.
narcolepsy type 1 (NT1). While the effects of orexin receptor
Sleep Disturbances in Autoimmune Neurological Diseases.
narcolepsy, anti-IgLON5 disease). An immune-mediated damage of the areas
Plasticity of the hypocretinergic/orexinergic system after a chronic treatment with suvorexant in rats. Role of the hypocretinergic/orexinergic receptor 1 as an autoreceptor.
narcolepsy, a sleep disease caused in humans by progressive neurodegeneration
10.1038/s41598-024-70594-1
Narcolepsy type 1 (NT1) is associated with severe loss of orexin
Hypocretins (orexins): The ultimate translational neuropeptides.
narcolepsy with cataplexy (narcolepsy type 1), a disorder characterized by intrusions
Excessive daytime sleepiness in parkinsonism.
narcolepsy-like phenotype, identified on multiple-sleep latency tests, occurs
TAK-925, an orexin 2 receptor-selective agonist, shows robust wake-promoting effects in mice.
narcolepsy type 1 (NT1). Orexin peptides act on two G protein
Coexistence of narcolepsy and Alzheimer's disease.
narcolepsy. We found that AD was present in 4 of these
A commentary on the neurobiology of the hypocretin/orexin system.
narcolepsy in mice, dogs and humans. Effects on appetite, neuroendocrine
Hypocretin/orexin in arousal and stress.
narcolepsy. Combined, these observations suggested that HCRT might be a key transmitter
Hypocretin/Orexin Receptor Pharmacology and Sleep Phases.
narcolepsy. The involvement of this system in a disorder characterized
The development of hypocretin (orexin) deficiency in hypocretin/ataxin-3 transgenic rats.
Narcolepsy is linked to a widespread loss of neurons containing
Comparative abuse liability of GHB and ethanol in humans.
narcolepsy symptom treatment, and it is also abused. This study
Conditions of primary excessive daytime sleepiness.
narcolepsy, much more remains to be understood, and far less